ZOLYMBUS Drug Patent Profile

When do Zolymbus patents expire, and what generic alternatives are available?

Zolymbus is a drug marketed by Thea Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in ZOLYMBUS is bimatoprost. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zolymbus

A generic version of ZOLYMBUS was approved as bimatoprost by SANDOZ on May 5^th, 2015.

Summary for ZOLYMBUS

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ZOLYMBUS?	ZOLYMBUS excipients list
DailyMed Link:	ZOLYMBUS at DailyMed

Pharmacology for ZOLYMBUS

Drug Class

Prostaglandin Analog

US Patents and Regulatory Information for ZOLYMBUS

ZOLYMBUS is protected by one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	ZOLYMBUS	bimatoprost	GEL;OPHTHALMIC	217307-001	Sep 9, 2025		RX	Yes	Yes			Y
Thea Pharma	ZOLYMBUS	bimatoprost	GEL;OPHTHALMIC	217307-001	Sep 9, 2025		RX	Yes	Yes

International Patents for ZOLYMBUS

See the table below for patents covering ZOLYMBUS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016277336
Brazil	112017026552
Canada	2985897
China	107771074
Cyprus	1120883
Denmark	3307241

Supplementary Protection Certificates for ZOLYMBUS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	SPC/GB02/035	United Kingdom		PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716	C300099	Netherlands		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716	02C0033	France		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:

ZOLYMBUS market dynamics and financial trajectory: exclusivity, competitive threats, and revenue outlook

Last updated: May 28, 2026

ZOLYMBUS is a branded pharmaceutical product whose market dynamics and financial trajectory cannot be quantified from the information provided. A complete, accurate market-and-patent financial outlook requires the drug’s FDA/EMA status, active ingredient, strength and dosage form, manufacturer, pricing and revenue baseline, and the patent and exclusivity record (Orange Book and litigation/certification history). Without those inputs, any revenue exposure, generic or biosimilar risk timing, or defensible financial forecast would be incomplete.

What is ZOLYMBUS and what active ingredient does it contain?

No market dynamics or financial trajectory analysis can be produced without the drug’s active ingredient, route of administration, dosage forms, and the current approved indications (and the FDA application holder). These determine:

• whether competition is primarily generic, authorized generic, OTC switch, or biologics pathway (BLA, biosimilar)
• whether exclusivity is driven by NCE/505(b)(2)/PDUFA/biologics exclusivity mechanics
• the relevant therapeutic peer set and reimbursement environment

What indications drive payer coverage and utilization for ZOLYMBUS?

Indication scope controls addressable market, patient flow, and contracting leverage. Without ZOLYMBUS indication and label details, there is no basis to estimate utilization, premium pricing capacity, or time-to-loss of exclusivity.

Which companies market ZOLYMBUS and what is the distribution footprint?

Distribution model and channel mix (hospital vs retail, specialty pharmacy vs buy-and-bill) drive revenue timing, chargebacks, and net-to-gross. No company identifiers are provided.

What patents protect ZOLYMBUS and when do they expire?

A financial trajectory is inseparable from the ZOLYMBUS patent estate. Without the specific Orange Book listings (application number, patent numbers, listed expiration dates, and exclusivity end dates) and any method-of-use or formulation patents, launch-risk timing cannot be established.

Which Orange Book patents are listed for ZOLYMBUS?

No Orange Book patent numbers, expiration dates, or claims-by-patent mapping are provided, so market exclusivity timing cannot be anchored.

Do method-of-use or formulation patents constrain generic entry for ZOLYMBUS?

Method-of-use and formulation claims can delay Paragraph IV certainty and settlement timing. No patent claim categories are available for ZOLYMBUS.

When does ZOLYMBUS lose exclusivity under FDA rules (NCE, 5-year, 3-year, pediatric)

No exclusivity end date data is provided. As a result, there is no defensible determination of:

• earliest possible ANDA approval
• earliest possible generic launch window under FTC settlement timelines
• pediatric exclusivity extension mechanics

How much exclusivity runway does ZOLYMBUS have before generic approval?

This requires FDA approval date and exclusivity type. Not provided.

What generic launch risks exist for ZOLYMBUS (Paragraph IV, ANDA filings, settlements)?

Market dynamics depend on whether the first-to-file ANDA is filed with Paragraph IV certifications tied to specific listed patents and whether litigation led to settlement-triggered entry dates.

Have ANDAs been filed for ZOLYMBUS and which patents are challenged?

No Paragraph IV certification details, ANDA case numbers, or challenged-patent lists are provided.

What settlement agreements or launch dates affect ZOLYMBUS revenue?

No settlement facts or trigger dates are provided.

What is the Orange Book status of ZOLYMBUS (listed patents, exclusivity, application numbers)?

No Orange Book status content is provided (drug product, NDA/BLA, application numbers, listed patents, and expiration dates). This blocks any timeline-driven market modeling.

How does ZOLYMBUS compare with therapeutic competitors on patents and likely share loss?

A financial trajectory requires a peer set with:

• competing products’ patent expiration dates and exclusivity status
• comparable mechanism-of-action and label positioning
• relative pricing and contracting position

No therapeutic class or peer products are supplied.

What litigation affects ZOLYMBUS market access (Hatch-Waxman, state, or PTAB challenges)?

Patent litigation drives entry timing, injunction risk, and settlement economics. No case history is provided (plaintiffs, defendants, asserted patents, filing dates, rulings, or appeals).

What patent cases are currently active for ZOLYMBUS?

No docket or litigation status exists in the provided information.

Which courts or PTAB proceedings could alter ZOLYMBUS patent strength?

No invalidity or reexamination postures are provided.

What formulations are protected by ZOLYMBUS patents and what manufacturing/IP barriers exist?

Formulation and manufacturing method patents can block simple design-around and increase generic cost or require longer regulatory timelines (stability, bioequivalence, CMC updates).

No ZOLYMBUS formulation patents or manufacturing process IP are provided.

What is the FDA regulatory status of ZOLYMBUS (NDA/BLA, pathway, label maturity)?

FDA pathway impacts marketing timeline, labeling changes, and exclusivity. Without:

• NDA/BLA number
• approval date and supplements
• manufacturing site status and REMS (if any) there is no basis for an FDA-driven revenue forecast.

Is ZOLYMBUS approved under 505(b)(1), 505(b)(2), or BLA biologics pathway?

Pathway is not provided.

What commercial metrics define ZOLYMBUS financial trajectory (net sales, YoY growth, pricing, rebates)?

No financial baselines, pricing, payer contracting details, or disclosed net sales are provided. Without those, a trajectory cannot be computed.

What are ZOLYMBUS net sales and growth drivers (volume vs price vs mix)?

Drivers require revenue series and channel mix. Not provided.

What rebate and pricing pressure does ZOLYMBUS face?

No payer contracting or reimbursement environment is provided.

What biosimilar risk exists for ZOLYMBUS?

Biosimilar risk applies only if ZOLYMBUS is a biologic (BLA, reference product). ZOLYMBUS pathway and molecule type are not provided.

Could a biosimilar enter before ZOLYMBUS patent expiry?

This depends on biologics exclusivity and BPCIA patent dance timeline. No biologic status is provided.

Which geographic markets matter most for ZOLYMBUS (US, EU, UK, ex-US royalties)?

Market dynamics differ by:

• local reimbursement
• price controls and tendering
• local patent term and SPC availability

No geography or commercial rights holder is provided.

---

Key Takeaways

• ZOLYMBUS market dynamics and financial trajectory cannot be quantified from the provided inputs because the drug identity, FDA regulatory record, Orange Book patent and exclusivity timing, litigation/Paragraph IV posture, and commercial baseline data are not specified.
• A defensible revenue outlook depends on exact NDA/BLA identifiers, listed patents with expiration dates, exclusivity end dates, and any ANDA/biosimilar filing and litigation triggers.
• Competitor share-loss modeling requires ZOLYMBUS mechanism, label scope, and the peer patent wall timelines.

FAQs

1. How do Orange Book listed patents drive generic launch timing for ZOLYMBUS?
2. What is the earliest possible generic entry date for ZOLYMBUS after patent expiry?
3. How do Paragraph IV challenges and FTC settlement triggers affect ZOLYMBUS net sales decline curves?
4. Does ZOLYMBUS face biosimilar competition under BPCIA, and when could it launch?
5. What are the most likely ZOLYMBUS revenue headwinds: pricing cuts, formulary changes, or patent cliff?

References

No sources can be cited because no ZOLYMBUS-specific FDA, Orange Book, patent, litigation, or financial data was provided.